48 related articles for article (PubMed ID: 19553524)
21. CD4-BFFI: a novel, bifunctional HIV-1 entry inhibitor with high and broad antiviral potency.
Jekle A; Chow E; Kopetzki E; Ji C; Yan MJ; Nguyen R; Sankuratri S; Cammack N; Heilek G
Antiviral Res; 2009 Sep; 83(3):257-66. PubMed ID: 19559732
[TBL] [Abstract][Full Text] [Related]
22. HIV pseudovirion vaccine exposing Env "fusion intermediates"-response to immunisation in human CD4/CCR5-transgenic rats.
Bosch V; Pfeiffer T; Devitt G; Allespach I; Ebensen T; Emerson V; Guzman CA; Keppler OT
Vaccine; 2009 Apr; 27(16):2202-12. PubMed ID: 19428834
[TBL] [Abstract][Full Text] [Related]
23. Enhanced HIV-1 neutralization by a CD4-VH3-IgG1 fusion protein.
Meyuhas R; Noy H; Fishman S; Margalit A; Montefiori DC; Gross G
Biochem Biophys Res Commun; 2009 Aug; 386(2):402-6. PubMed ID: 19538939
[TBL] [Abstract][Full Text] [Related]
24. [Towards a vaccine for HIV infection: role of the gp41 envelope protein].
Debre P; Costagliola D; Legrand R; Vieillard V
Bull Acad Natl Med; 2009 Jan; 193(1):127-36; discussion 137-8. PubMed ID: 19718985
[TBL] [Abstract][Full Text] [Related]
25. Reduction of HIV-1 infectivity through endoplasmic reticulum-associated degradation-mediated Env depletion.
Casini A; Olivieri M; Vecchi L; Burrone OR; Cereseto A
J Virol; 2015 Mar; 89(5):2966-71. PubMed ID: 25540359
[TBL] [Abstract][Full Text] [Related]
26. Efficient magnetic bead-based separation of HIV-1-infected cells using an improved reporter virus system reveals that p53 up-regulation occurs exclusively in the virus-expressing cell population.
Imbeault M; Lodge R; Ouellet M; Tremblay MJ
Virology; 2009 Oct; 393(1):160-7. PubMed ID: 19692106
[TBL] [Abstract][Full Text] [Related]
27. Molecular characterization of the env gene of two CCR5/CXCR4-independent human immunodeficiency 2 primary isolates.
Santos-Costa Q; Parreira R; Moniz-Pereira J; Azevedo-Pereira JM
J Med Virol; 2009 Nov; 81(11):1869-81. PubMed ID: 19774680
[TBL] [Abstract][Full Text] [Related]
28. Narrowed TCR diversity for immunised mice challenged with recombinant influenza A-HIV Env(311-320) virus.
Cukalac T; Moffat JM; Venturi V; Davenport MP; Doherty PC; Turner SJ; Stambas J
Vaccine; 2009 Nov; 27(48):6755-61. PubMed ID: 19744584
[TBL] [Abstract][Full Text] [Related]
29. Structure and function of HIV-1 CRF01_AE envelope proteins from blood and genital fluid isolates.
Horthongkham N; Athipanyasilp N; Siritantikorn S; Kantakamalakul W; Srisurapanon S; Sutthent R
Southeast Asian J Trop Med Public Health; 2009 May; 40(3):480-93. PubMed ID: 19842433
[TBL] [Abstract][Full Text] [Related]
30. Screening HIV-1 antigenic peptides as receptors for antibodies and CD4 in allosteric nanosensors.
Ferraz RM; Rodríguez-Carmona E; Ferrer-Miralles N; Meyerhans A; Villaverde A
J Mol Recognit; 2009; 22(3):255-60. PubMed ID: 19177495
[TBL] [Abstract][Full Text] [Related]
31. Identification and characterization of a highly efficient anti-HIV pol hammerhead ribozyme.
Müller-Kuller T; Capalbo G; Klebba C; Engels JW; Klein SA
Oligonucleotides; 2009 Sep; 19(3):265-72. PubMed ID: 19732019
[TBL] [Abstract][Full Text] [Related]
32. Expression and purification of soluble HIV-1 envelope glycoprotein gp160 mutant from Saccharomyces cerevisiae.
Yang K; Li S; He F; Zhang J; Wei M; Pan H; Yang C; Xiong J; Zhang J; Xia N
J Biosci Bioeng; 2009 Jul; 108(1):5-10. PubMed ID: 19577184
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of porcine endogenous retrovirus (PERV) replication by HIV-1 gene expression inhibitors.
Shi M; Wang X; Okamoto M; Takao S; Baba M
Antiviral Res; 2009 Aug; 83(2):201-4. PubMed ID: 19414036
[TBL] [Abstract][Full Text] [Related]
34. Discovery of a small molecule inhibitor through interference with the gp120-CD4 interaction.
Williams DH; Adam F; Fenwick DR; Fok-Seang J; Gardner I; Hay D; Jaiessh R; Middleton DS; Mowbray CE; Parkinson T; Perros M; Pickford C; Platts M; Randall A; Siddle D; Stephenson PT; Tran TD; Vuong H
Bioorg Med Chem Lett; 2009 Sep; 19(17):5246-9. PubMed ID: 19620004
[TBL] [Abstract][Full Text] [Related]
35. Journal club. A structural biologist has great expectations for llamas' small antibodies.
Hwang WC
Nature; 2009 May; 459(7245):303. PubMed ID: 19458671
[No Abstract] [Full Text] [Related]
36. Expression of a modified form of CD4 results in the release of an anti-HIV factor derived from the Env sequence.
Zaldívar I; Muñoz-Fernández MA; Alarcón B; San José E
J Immunol; 2009 Jul; 183(2):1188-96. PubMed ID: 19553524
[TBL] [Abstract][Full Text] [Related]
37. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network.
Zhou P; Goldstein S; Devadas K; Tewari D; Notkins AL
J Immunol; 1998 Feb; 160(3):1489-96. PubMed ID: 9570571
[TBL] [Abstract][Full Text] [Related]
38. Mutational analysis of HIV-1 gp160-mediated receptor interference: intracellular complex formation.
Martin RA; Nayak DP
Virology; 1996 Jun; 220(2):461-72. PubMed ID: 8661396
[TBL] [Abstract][Full Text] [Related]
39. Retroviral vector-mediated expression in primary human T cells of an endoplasmic reticulum-retained CD4 chimera inhibits human immunodeficiency virus type-1 replication.
San José E; Muñoz-Fernández MA; Alarcón B
Hum Gene Ther; 1998 Jun; 9(9):1345-57. PubMed ID: 9650619
[TBL] [Abstract][Full Text] [Related]
40. The HIV-1 Env protein signal sequence retards its cleavage and down-regulates the glycoprotein folding.
Li Y; Luo L; Thomas DY; Kang CY
Virology; 2000 Jul; 272(2):417-28. PubMed ID: 10873786
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
